دورية أكاديمية
أعرض في EDS

Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).

التفاصيل البيبلوغرافية
العنوان: Experimental Nonalcoholic Steatohepatitis and Liver Fibrosis Are Ameliorated by Pharmacologic Activation of Nrf2 (NF-E2 p45-Related Factor 2).
المؤلفون: Sharma RS; Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Harrison DJ; School of Medicine, University of St Andrews, St Andrews, Scotland, United Kingdom., Kisielewski D; Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Cassidy DM; Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom.; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., McNeilly AD; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Gallagher JR; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Walsh SV; Department of Pathology, Ninewells Hospital and Medical School, Tayside NHS Trust, Dundee, Scotland, United Kingdom., Honda T; Department of Chemistry and Institute of Chemical Biology & Drug Discovery, Stony Brook University, Stony Brook, New York., McCrimmon RJ; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Dinkova-Kostova AT; Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Ashford MLJ; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Dillon JF; Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom., Hayes JD; Division of Cancer Research, Ninewells Hospital and Medical School, University of Dundee, Dundee, Scotland, United Kingdom.
المصدر: Cellular and molecular gastroenterology and hepatology [Cell Mol Gastroenterol Hepatol] 2017 Dec 13; Vol. 5 (3), pp. 367-398. Date of Electronic Publication: 2017 Dec 13 (Print Publication: 2018).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: American Gastroenterological Association Country of Publication: United States NLM ID: 101648302 Publication Model: eCollection Cited Medium: Print ISSN: 2352-345X (Print) Linking ISSN: 2352345X NLM ISO Abbreviation: Cell Mol Gastroenterol Hepatol Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : American Gastroenterological Association, [2015]-
مستخلص: Background & Aims: Nonalcoholic steatohepatitis (NASH) is associated with oxidative stress. We surmised that pharmacologic activation of NF-E2 p45-related factor 2 (Nrf2) using the acetylenic tricyclic bis(cyano enone) TBE-31 would suppress NASH because Nrf2 is a transcriptional master regulator of intracellular redox homeostasis.
Methods: Nrf2 +/+ and Nrf2 -/- C57BL/6 mice were fed a high-fat plus fructose (HFFr) or regular chow diet for 16 weeks or 30 weeks, and then treated for the final 6 weeks, while still being fed the same HFFr or regular chow diets, with either TBE-31 or dimethyl sulfoxide vehicle control. Measures of whole-body glucose homeostasis, histologic assessment of liver, and biochemical and molecular measurements of steatosis, endoplasmic reticulum (ER) stress, inflammation, apoptosis, fibrosis, and oxidative stress were performed in livers from these animals.
Results: TBE-31 treatment reversed insulin resistance in HFFr-fed wild-type mice, but not in HFFr-fed Nrf2-null mice. TBE-31 treatment of HFFr-fed wild-type mice substantially decreased liver steatosis and expression of lipid synthesis genes, while increasing hepatic expression of fatty acid oxidation and lipoprotein assembly genes. Also, TBE-31 treatment decreased ER stress, expression of inflammation genes, and markers of apoptosis, fibrosis, and oxidative stress in the livers of HFFr-fed wild-type mice. By comparison, TBE-31 did not decrease steatosis, ER stress, lipogenesis, inflammation, fibrosis, or oxidative stress in livers of HFFr-fed Nrf2-null mice.
Conclusions: Pharmacologic activation of Nrf2 in mice that had already been rendered obese and insulin resistant reversed insulin resistance, suppressed hepatic steatosis, and mitigated against NASH and liver fibrosis, effects that we principally attribute to inhibition of ER, inflammatory, and oxidative stress.
References: Methods Mol Biol. 2012;821:421-33. (PMID: 22125082)
Int J Mol Sci. 2013 Oct 15;14(10):20704-28. (PMID: 24132155)
Trends Endocrinol Metab. 2016 Oct;27(10 ):719-730. (PMID: 27387598)
Biochem Biophys Res Commun. 1997 Jul 18;236(2):313-22. (PMID: 9240432)
Annu Rev Biochem. 2005;74:739-89. (PMID: 15952902)
Free Radic Biol Med. 2016 Oct;99:520-532. (PMID: 27634173)
Arch Biochem Biophys. 2016 Feb 1;591:57-65. (PMID: 26701603)
Mol Cancer Ther. 2016 Dec;15(12 ):3000-3014. (PMID: 27638861)
Diabetes. 2011 Nov;60(11):3055-66. (PMID: 22025779)
Sci Rep. 2016 Apr 14;6:24399. (PMID: 27075683)
Biol Chem. 2014 Feb;395(2):203-30. (PMID: 24127541)
Methods Enzymol. 2004;382:243-58. (PMID: 15047106)
Genes Dev. 2014 Apr 1;28(7):708-22. (PMID: 24636985)
Biochim Biophys Acta. 2011 Dec;1811(12):1194-200. (PMID: 21840420)
Nat Commun. 2016 May 23;7:11624. (PMID: 27211851)
Trends Endocrinol Metab. 2017 Apr;28(4):250-260. (PMID: 27986466)
J Biol Chem. 2004 Aug 13;279(33):34898-902. (PMID: 15184376)
Hepatology. 2013 Jun;57(6):2525-31. (PMID: 23390127)
Antioxid Redox Signal. 2011 Oct 15;15(8):2135-46. (PMID: 21504366)
Hepatology. 2011 Mar;53(3):810-20. (PMID: 21319198)
Cell Metab. 2007 Jan;5(1):73-9. (PMID: 17189208)
J Gastroenterol. 2012 Aug;47(8):924-35. (PMID: 22367278)
Mol Cell Endocrinol. 2015 Sep 5;412:36-43. (PMID: 26001833)
Lipids Health Dis. 2013 Nov 04;12:165. (PMID: 24188280)
Nat Rev Mol Cell Biol. 2015 Nov;16(11):678-89. (PMID: 26490400)
Hepatology. 2013 Oct;58(4):1497-507. (PMID: 23299992)
Trends Biochem Sci. 2014 Apr;39(4):199-218. (PMID: 24647116)
Cell. 2010 Mar 19;140(6):900-17. (PMID: 20303879)
J Biol Chem. 2010 Oct 29;285(44):33747-55. (PMID: 20801881)
Hepatology. 2009 Jun;49(6):1913-25. (PMID: 19378344)
J Gastroenterol. 2013 May;48(5):620-32. (PMID: 22972520)
J Proteome Res. 2013 Apr 5;12(4):1956-68. (PMID: 23473242)
Free Radic Biol Med. 2010 Jan 15;48(2):357-71. (PMID: 19914374)
Dev Cell. 2008 Dec;15(6):829-40. (PMID: 19081072)
Annu Rev Physiol. 2016;78:181-205. (PMID: 26667070)
Nat Rev Mol Cell Biol. 2007 Jul;8(7):519-29. (PMID: 17565364)
Mol Cell Biol. 2004 Dec;24(23 ):10161-8. (PMID: 15542827)
Antioxid Redox Signal. 2014 Jul 20;21(3):396-413. (PMID: 24702237)
J Cell Sci. 2014 Sep 1;127(Pt 17):3649-58. (PMID: 25107370)
Hepatology. 2011 May;53(5):1752-63. (PMID: 21384408)
Hepatology. 2010 Nov;52(5):1836-46. (PMID: 21038418)
Eur J Pharmacol. 2014 Sep 5;738:310-8. (PMID: 24937020)
Toxicol Appl Pharmacol. 2010 Jun 15;245(3):326-34. (PMID: 20350562)
Mol Cell Biol. 2014 Sep;34(17):3305-20. (PMID: 24958099)
Science. 2008 Jun 13;320(5882):1492-6. (PMID: 18556558)
Nat Rev Gastroenterol Hepatol. 2017 Jun;14 (6):343-355. (PMID: 28428634)
Endocrinology. 2007 Oct;148(10 ):4667-75. (PMID: 17628006)
Front Cell Neurosci. 2014 Jul 29;8:213. (PMID: 25120434)
Mol Endocrinol. 2002 Mar;16(3):506-14. (PMID: 11875109)
Am J Physiol Gastrointest Liver Physiol. 2010 Feb;298(2):G283-94. (PMID: 19926817)
Mol Cell Biol. 2013 Aug;33(15):2996-3010. (PMID: 23716596)
Cell Mol Life Sci. 2009 Sep;66(17):2835-50. (PMID: 19468685)
Mol Cell Biochem. 2013 Sep;381(1-2):127-37. (PMID: 23703028)
J Biol Chem. 2010 Dec 24;285(52):40581-92. (PMID: 20956520)
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):656-65. (PMID: 24080776)
Sci Transl Med. 2017 Jun 14;9(394):null. (PMID: 28615356)
Cell Metab. 2008 Jun;7(6):520-32. (PMID: 18522833)
J Lipid Res. 2004 Nov;45(11):2052-62. (PMID: 15292368)
Diabetes. 2012 Dec;61(12 ):3208-18. (PMID: 22936178)
J Med Chem. 2011 Mar 24;54(6):1762-78. (PMID: 21361338)
Toxicol Appl Pharmacol. 2012 Nov 1;264(3):431-8. (PMID: 22959925)
Mol Pharmacol. 2013 Jul;84(1):62-70. (PMID: 23592516)
Am J Physiol Endocrinol Metab. 2002 Apr;282(4):E834-42. (PMID: 11882503)
Free Radic Biol Med. 2016 Feb;91:114-26. (PMID: 26698665)
Free Radic Biol Med. 2013 Aug;61:85-94. (PMID: 23507082)
Biochim Biophys Acta. 2015 Jan;1852(1):156-65. (PMID: 25458704)
Diabetes. 2010 Apr;59(4):850-60. (PMID: 20103708)
معلومات مُعتمدة: MR/J001465/1 United Kingdom MRC_ Medical Research Council; MR/N009851/1 United Kingdom MRC_ Medical Research Council
فهرسة مساهمة: Keywords: ACACA, acetyl-CoA carboxylase alpha; ACLY, ATP citrate lyase; ACOT7, acetyl-CoA thioesterase 7; ACOX2, acetyl-CoA oxidase 2; ADRP, adipose differentiation-related protein; AP-1, activator protein 1; ATF4, activating transcription factor-4; ATF6, activating transcription factor-6; ApoB, apolipoprotein B; BCL-2, B-cell lymphoma; BIP, binding immunoglobulin protein; C/EBP, CCAAT/enhancer-binding protein; CAT, catalase; CD36, cluster of differentiation 36; CDDO, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid; CES1G, carboxylesterase 1g; CHOP, C/EBP homologous protein; COL1A1, collagen, type I, alpha-1; COX2, cyclooxygenase-2; CPT1A, carnitine palmitoyltransferase 1a; ChREBP, carbohydrate-responsive element-binding protein; DGAT2, diacylglycerol acyltransferase-2; DMSO, dimethyl sulfoxide; ER, endoplasmic reticulum; FASN, fatty acid synthase; FXR, farnesoid X receptor; GCLC, glutamate-cysteine ligase catalytic; GCLM, glutamate-cysteine ligase modifier; GPX2, glutathione peroxidase-2; GSH, reduced glutathione; GSSG, oxidized glutathione; GSTA4, glutathione S-transferase Alpha-4; GSTM1, glutathione S-transferase Mu-1; GTT, glucose tolerance test; H&E, hematoxylin and eosin; HF, high-fat; HF30Fr, high-fat diet with 30% fructose in drinking water; HF55Fr, high-fat diet with 55% fructose in drinking water; HFFr, high-fat diet with fructose in drinking water; HMOX1, heme oxygenase-1; IKK, IκB kinase; IRE1α, inositol requiring kinase-1α; ITT, insulin tolerance test; IκB, inhibitor of NF-κB; JNK1, c-Jun N-terminal kinase 1; Keap1, Kelch-like ECH-associated protein-1; LXRα, liver X receptor α; MCD, methionine- and choline-deficient; MCP-1, monocyte chemotactic protein-1; MGPAT, mitochondrial glycerol-3-phosphate acetyltransferase; MPO, myeloperoxidase; MTTP, microsomal triglyceride transfer protein; NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH; NASH, nonalcoholic steatohepatitis; NF-κB, nuclear factor-κB; NOS2, nitric oxide synthase-2; NQO1, NAD(P)H:quinone oxidoreductase 1; Nrf2; Nrf2, NF-E2 p45-related factor 2; PARP, poly ADP ribose polymerase; PCR, polymerase chain reaction; PDI, protein disulfide isomerase; PERK, PRK-like endoplasmic reticulum kinase; PPARα, peroxisome proliferator-activated receptor α; PPARγ, peroxisome proliferator-activated receptor γ; PRDX6, peroxiredoxin 6; PTGR1, prostaglandin reductase-1; PTT, pyruvate tolerance test; RC, regular chow; SCAD, short-chain acyl-CoA dehydrogenase; SCD1, stearoyl-CoA desaturase-1; SFN, sulforaphane; SHP, small heterodimer partner; SLC7A11, solute carrier family 7 member 11; SREBP-1c, sterol regulatory element-binding protein-1c; TBE-31; TGFβ, transforming growth factor beta-1; TNF-α, tumor necrosis factor-α; TXN1, thioredoxin-1; TXNRD1, thioredoxin reductase-1; UPR, unfolded protein response; XBP1, X-box binding protein-1; eIf2α, eukaryotic translation initiation factor 2A; p58IPK, p58 inhibitor of the PKR kinase; qRT-PCR, quantitative reverse transcriptase PCR; α-SMA, alpha smooth muscle actin
تواريخ الأحداث: Date Created: 20180320 Latest Revision: 20240214
رمز التحديث: 20240214
مُعرف محوري في PubMed: PMC5852394
DOI: 10.1016/j.jcmgh.2017.11.016
PMID: 29552625
قاعدة البيانات: MEDLINE
الوصف
تدمد:2352-345X
DOI:10.1016/j.jcmgh.2017.11.016